ARQT - Arcutis Biotherapeutics Inc logo

ARQT

Arcutis Biotherapeutics Inc

Rev —top 1%Revenue grew 100% of years5Y
Hold

Arcutis Biotherapeutics develops and commercializes treatments for dermatological diseases, focusing on immune-mediated conditions. Its primary products include ZORYVE, a cream for plaque psoriasis and atopic dermatitis, and ARQ-234, a CD200 receptor agonist.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $1,219today

Score Overview

1 Year
Score
Net Growth276.69%
Net TrendGrew
Net Income Consistency
Rev Growth23.38%
Rev TrendGrew
Revenue Consistency
5 Years
Score
Net Growth113.85%
Net Trend80%
Net Income Consistency
Rev Growth
Rev TrendEvery year
Revenue Consistency
All Time
Score
Net Growth121.02%
Net Trend67%
Net Income Consistency
Rev Growth
Rev Trend83%
Revenue Consistency

See the full market ranking →

Arcutis Biotherapeutics Inc fundamental performance

Across Arcutis Biotherapeutics Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 376M and net income went from -$ 135M to -$ 16M. Revenue increased in 83% of the years measured; net income in 67%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 26.28
1 Year2025-08-12
$ 14.7478.29%
5 Years2021-08-12
$ 21.5621.89%
All Time2020-01-31
$ 21.8020.55%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 463M$ 28M$ 238M
2025$ 376M-$ 16M$ 220M
2024$ 196M-$ 140M$ 227M
2023$ 59M-$ 262M$ 271M
2022$ 3M-$ 311M$ 409M
2021$ 0.00-$ 205M$ 388M
IPO2020$ 0.00-$ 135M$ 284M

Explore beyond ARQT

You're looking at Arcutis Biotherapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies